留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

成纤维细胞生长因子受体1在非小细胞肺癌中的研究进展

刘磊 张家齐 王桂阁 黄诚 李力 梁乃新 李单青

刘磊, 张家齐, 王桂阁, 黄诚, 李力, 梁乃新, 李单青. 成纤维细胞生长因子受体1在非小细胞肺癌中的研究进展[J]. 协和医学杂志, 2019, 10(6): 666-672. doi: 10.3969/j.issn.1674-9081.2019.06.020
引用本文: 刘磊, 张家齐, 王桂阁, 黄诚, 李力, 梁乃新, 李单青. 成纤维细胞生长因子受体1在非小细胞肺癌中的研究进展[J]. 协和医学杂志, 2019, 10(6): 666-672. doi: 10.3969/j.issn.1674-9081.2019.06.020
Lei LIU, Jia-qi ZHANG, Gui-ge WANG, Cheng HUANG, Li LI, Nai-xin LIANG, Shan-qing LI. Fibroblast Growth Factor Receptor 1 in Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 666-672. doi: 10.3969/j.issn.1674-9081.2019.06.020
Citation: Lei LIU, Jia-qi ZHANG, Gui-ge WANG, Cheng HUANG, Li LI, Nai-xin LIANG, Shan-qing LI. Fibroblast Growth Factor Receptor 1 in Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 666-672. doi: 10.3969/j.issn.1674-9081.2019.06.020

成纤维细胞生长因子受体1在非小细胞肺癌中的研究进展

doi: 10.3969/j.issn.1674-9081.2019.06.020
详细信息
    通讯作者:

    李单青 电话:010-69152630, E-mail:lidanqing@pumch.cn

  • 中图分类号: R734.2;R-1

Fibroblast Growth Factor Receptor 1 in Non-small Cell Lung Cancer

More Information
  • 摘要: 非小细胞肺癌(non-small cell lung cancer, NSCLC)已成为全世界癌症患者死亡的主要原因之一, 其治疗成为目前研究热点。但NSCLC中成纤维细胞生长因子受体(fibroblast growth factor receptor, FGFR)基因突变以及间变性淋巴瘤激酶(anaplastic lymphoma kinase, ALK)融合基因发生率低, 相应靶向药物治疗的总体效果并不理想。FGFR1作为NSCLC中较常见的异常基因, 其异常扩增高表达与多种肿瘤的发生发展相关, 同时发现多种相关的分子靶向药物对肿瘤有抑制作用。本文对FGFR1在NSCLC中的扩增高表达情况、其与NSCLC临床特点之间的关系以及目前相关靶向药物治疗研究进展作一综述。
    利益冲突  无
  • [1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67:7-30. doi:  10.3322/caac.21387
    [2] Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project:Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer[J]. J Thorac Oncol, 2015, 10:1675-1684. doi:  10.1097/JTO.0000000000000678
    [3] Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC Lung Cancer Staging Project:External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer[J]. J Thorac Oncol, 2017, 12:1109-1121. doi:  10.1016/j.jtho.2017.04.011
    [4] Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer[J]. PLoS One, 2011, 6:e20351. doi:  10.1371/journal.pone.0020351
    [5] Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer[J]. Sci Transl Med, 2010, 2:62ra93. http://bioinformatics.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=scitransmed&resid=2/62/62ra93
    [6] Malchers F, Dietlein F, Schottle J, et al. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer[J]. Cancer Discov, 2014, 4:246-257. doi:  10.1158/2159-8290.CD-13-0323
    [7] Turner NC, Seckl MJ. A therapeutic target for smoking-associated lung cancer[J]. Sci Transl Med, 2010, 2:62ps56. http://www.ncbi.nlm.nih.gov/pubmed/21160076/
    [8] Prié D, Friedlander G. Reciprocal control of 1, 25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system[J]. Clin J Am Soc Nephrol, 2010, 5:1717-1722. doi:  10.2215/CJN.02680310
    [9] Olsen SK, Ibrahimi OA, Raucci A, et al. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity[J]. Proc Natl Acad Sci U S A, 2004, 101:935-940. doi:  10.1073/pnas.0307287101
    [10] Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation[J]. Cytokine Growth Factor Rev, 2005, 16:107-137. doi:  10.1016/j.cytogfr.2005.01.008
    [11] Marek L, Ware KE, Fritzsche A, et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells[J]. Mol Pharmacol, 2009, 75:196-207. doi:  10.1124/mol.108.049544
    [12] Pros E, Lantuejoul S, Sanchez-Verde L, et al. Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer[J]. Int J Cancer, 2013, 133:898-907. doi:  10.1002/ijc.28090
    [13] Kim HR, Kim DJ, Kang DR, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer[J]. J Clin Oncol, 2013, 31:731-737. doi:  10.1200/JCO.2012.43.8622
    [14] Heist RS, Mino-Kenudson M, Sequist LV, et al. FGFR1 amplification in squamous cell carcinoma of the lung[J]. J Thorac Oncol, 2012, 7:1775-1780. doi:  10.1097/JTO.0b013e31826aed28
    [15] Schildhaus HU, Heukamp LC, Merkelbach-bruse S, et al. Definition of a fluorescence in-situ hybridization score iden-tifies high-and low-level FGFR1 amplification types in squa-mous cell lung cancer[J]. Mod Pathol, 2012, 25:1473-1480. doi:  10.1038/modpathol.2012.102
    [16] Rooney C, Geh C, Williams V, et al. Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon[J]. PLoS One, 2016, 11:e0149628. doi:  10.1371/journal.pone.0149628
    [17] Gadgeel SM, Chen W, Cote ML, et al. Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR[J]. PLoS One, 2013, 8:e79820. doi:  10.1371/journal.pone.0079820
    [18] Sasaki H, Shitara M, Yokota K, et al. Increased FGFR1 copy number in lung squamous cell carcinomas[J]. Mol Med Rep, 2012, 5:725-728. http://www.ncbi.nlm.nih.gov/pubmed/22179561
    [19] Ornitz DM, Itoh N. Fibroblast growth factors[J]. Genome Biol, 2001, 2: Reviews3005.
    [20] Stachowiak MK, Maher PA, Stachowiak EK. Integrative nuclear signaling in cell development-a role for FGF receptor-1[J]. DNA Cell Biol, 2007, 26:811-826. doi:  10.1089/dna.2007.0664
    [21] Powell PP, Wang CC, Horinouchi H, et al. Differential expression of fibroblast growth factor receptors 1 to 4 and ligand genes in late fetal and early postnatal rat lung[J]. Am J Respir Cell Mol Biol, 1998, 19:563-572. doi:  10.1165/ajrcmb.19.4.2994
    [22] Hyder SM, Murthy L, Stancel GM. Progestin regulation of vascular endothelial growth factor in human breast cancer cells[J]. Cancer Res, 1998, 58:392-395.
    [23] Schafer MH, Lingohr P, Strasser A, et al. Fibroblast growth factor receptor 1 gene amplification in gastric adenocar-cinoma[J]. Hum Pathol, 2015, 46:1488-1495. doi:  10.1016/j.humpath.2015.06.007
    [24] Kwak Y, Nam SK, Seo AN, et al. Fibroblast Growth Factor Receptor 1 Gene Copy Number and mRNA Expression in Primary Colorectal Cancer and Its Clinicopathologic Correlation[J]. Pathobiology, 2015, 82:76-83. doi:  10.1159/000398807
    [25] Fernanda Amary M, Ye H, Berisha F, et al. Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy[J]. Cancer Med, 2014, 3:980-987. doi:  10.1002/cam4.268
    [26] Behrens C, Lin HY, Lee JJ, et al. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer[J]. Clin Cancer Res, 2008, 14:6014-6022. doi:  10.1158/1078-0432.CCR-08-0167
    [27] Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers[J]. Nature, 2010, 463:899-905. doi:  10.1038/nature08822
    [28] Soundararajan P, Fawcett JP, Rafuse VF. Guidance of postural motoneurons requires MAPK/ERK signaling downstream of fibroblast growth factor receptor 1[J]. J Neurosci, 2010, 30:6595-6606. doi:  10.1523/JNEUROSCI.4932-09.2010
    [29] Kuslak SL, Marker PC. Fibroblast growth factor receptor signaling through MEK-ERK is required for prostate bud induction[J]. Differentiation, 2007, 75:638-651. doi:  10.1111/j.1432-0436.2006.00161.x
    [30] Williamson AJ, Dibling BC, Boyne JR, et al. Basic fibroblast growth factor-induced cell death is effected through sustained activation of p38MAPK and up-regulation of the death receptor p75NTR[J]. J Biol Chem, 2004, 279:47912-47928. doi:  10.1074/jbc.M409035200
    [31] Kranenburg AR, De Boer WI, Van Krieken JH, et al. Enhanced expression of fibroblast growth factors and receptor FGFR-1 during vascular remodeling in chronic obstructive pulmonary disease[J]. Am J Respir Cell Mol Biol, 2002, 27:517-525. doi:  10.1165/rcmb.4474
    [32] Kranenburg AR, Willems-widyastuti A, Mooi WJ, et al. Chronic obstructive pulmonary disease is associated with enhanced bronchial expression of FGF-1, FGF-2, and FGFR-1[J]. J Pathol, 2005, 206:28-38. doi:  10.1002/path.1748
    [33] Schwartz AG, Ruckdeschel JC. Familial lung cancer:genetic susceptibility and relationship to chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2006, 173:16-22. doi:  10.1164/rccm.200502-235PP
    [34] Ruotsalainen T, Joensuu H, Mattson K, et al. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer[J]. Cancer Epidemiol Biomarkers Prev, 2002, 11:1492-1495.
    [35] Joensuu H, Anttonen A, Eriksson M, et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer[J]. Cancer Res, 2002, 62:5210-5217. http://www.ncbi.nlm.nih.gov/pubmed/12234986/
    [36] Cihoric N, Savic S, Schneider S, et al. Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer[J]. Br J Cancer, 2014, 110:2914-2922. doi:  10.1038/bjc.2014.229
    [37] Cancer Genome Atlas Research Network.Comprehensive genomic characterization of squamous cell lung cancers[J]. Nature, 2012, 489:519-525. doi:  10.1038/nature11404
    [38] Preusser M, Berghoff AS, Berger W, et al. High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer[J]. Lung Cancer, 2014, 83:83-89. doi:  10.1016/j.lungcan.2013.10.004
    [39] Kohler LH, Mireskandari M, Knosel T, et al. FGFR1 expression and gene copy numbers in human lung cancer[J]. Virchows Arch, 2012, 461:49-57. doi:  10.1007/s00428-012-1250-y
    [40] Seo AN, Jin Y, Lee HJ, et al. FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer[J]. Virchows Arch, 2014, 465:547-558. doi:  10.1007/s00428-014-1634-2
    [41] Zhang J, Zhang L, Su X, et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models[J]. Clin Cancer Res, 2012, 18:6658-6667. doi:  10.1158/1078-0432.CCR-12-2694
    [42] Wang Y, Gao W, Xu J, et al. The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer:A Meta-Analysis of Published Data[J]. Bio Med Res Int, 2015, 2015:763080.
    [43] Zhang L, Yu H, Badzio A, et al. Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer[J]. J Thorac Oncol, 2015, 10:1083-1890. doi:  10.1097/JTO.0000000000000562
    [44] Xie FJ, Lu HY, Zheng QQ, et al. The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer:a meta-analysis[J]. Onco Targets Ther, 2016, 9:171-181. http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=112980396&site=ehost-live
    [45] Hibi M, Kaneda H, Tanizaki J, et al. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib[J]. Cancer Sci, 2016, 107:1667-1676. doi:  10.1111/cas.13071
    [46] Terai H, Soejima K, Yasuda H, et al. Activation of the FGF2-FGFR1 autocrine pathway:a novel mechanism of acquired resistance to gefitinib in NSCLC[J]. Mol Cancer Res, 2013, 11:759-767. doi:  10.1158/1541-7786.MCR-12-0652
    [47] Azuma K, Kawahara A, Sonoda K, et al. FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor[J]. Oncotarget, 2014, 5:5908-5919. doi:  10.18632/oncotarget.1866
    [48] Skaper SD, Kee WJ, Facci L, et al. The FGFR1 inhibitor PD 173074 selectively and potently antagonizes FGF-2 neurotrophic and neurotropic effects[J]. J Neurochem, 2000, 75:1520-1527.
    [49] Trudel S, Ely S, Farooqi Y, et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma[J]. Blood, 2004, 103:3521-3528. doi:  10.1182/blood-2003-10-3650
    [50] Goke A, Goke R, Ofner A, et al. The FGFR Inhibitor NVP-BGJ398 Induces NSCLC Cell Death by Activating Caspase-dependent Pathways as well as Caspase-independent Apoptosis[J]. Anticancer Res, 2015, 35:5873-5879.
    [51] Nogova L, Sequist LV, Perez Garcia JM, et al. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors:Results of a Global Phase Ⅰ, Dose-Escalation and Dose-Expansion Study[J]. J Clin Oncol, 2017, 35:157-165.
    [52] Gavine PR, Mooney L, Kilgour E, et al. AZD4547:an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family[J]. Cancer Res, 2012, 72:2045-2056. doi:  10.1158/0008-5472.CAN-11-3034
    [53] Ren M, Hong M, Liu G, et al. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1[J]. Oncol Rep, 2013, 29:2181-2190. doi:  10.3892/or.2013.2386
    [54] Wynes MW, Hinz TK, Gao D, et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies[J]. Clin Cancer Res, 2014, 20:3299-3309. doi:  10.1158/1078-0432.CCR-13-3060
    [55] Lim SH, Sun JM, Choi YL, et al. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification:A single-arm, phase 2 study[J]. Cancer, 2016, 122:3024-3031. doi:  10.1002/cncr.30135
    [56] Semrad TJ, Kim EJ, Tanaka MS, et al. Phase Ⅱ Study of Dovitinib in Patients Progressing on Anti-Vascular Endo-thelial Growth Factor Therapy[J]. Cancer Treat Res Commun, 2017, 10:21-26. doi:  10.1016/j.ctarc.2016.12.002
    [57] Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1):a phase 3, double-blind, randomised controlled trial[J]. Lancet Oncol, 2014, 15:143-155. doi:  10.1016/S1470-2045(13)70586-2
    [58] Hanna NH, Kaiser R, Sullivan RN, et al. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2):A randomized, double-blind, phase Ⅲ trial[J]. Lung Cancer, 2016, 102:65-73. doi:  10.1016/j.lungcan.2016.10.011
  • 加载中
计量
  • 文章访问数:  455
  • HTML全文浏览量:  29
  • PDF下载量:  138
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-10-13
  • 刊出日期:  2019-11-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!